

BOLSA DE INVESTIGAÇÃO (M/F)

Referência: FP7-HEALTH-2013-INNOVATION-1 - KINDRED

Título do Projecto: “Kinetoplastid Drug Development: strengthening the preclinical pipeline”

Código interno: PR301601

Está aberto concurso para recrutamento de um bolseiro de **investigação científica – licenciado**, para colaborar no projecto acima referido, financiado pelo “HEALTH.2013.2.3.4-2: Drug development for neglected parasitic diseases. FP7-HEALTH-2013-INNOVATION-1.”, através do Programa “Collaborative project - Small or medium-scale focused research project”.

A bolsa, em regime de exclusividade, terá a duração de 3 meses, com início previsto em 15 de fevereiro de 2016.

Os valor mensal da bolsas é: 745 euros

As bolsas são pagas por transferência bancária (preferencialmente).

Programa de trabalho: The trypanosomatid diseases, leishmaniasis, Human African trypanosomiasis (HAT) and Chagas disease (CD), continue to impart a heavy toll on human health. The treatments available are limited and threatened by drug resistance with few new drugs in the pipeline.

The KINDReD consortium integrates five leading academic laboratories in Europe (Portugal, United Kingdom, and Switzerland), the USA (California) and South America (Brazil) with high throughput screening (HTS) facilities equally distributed between all three major kinetoplastid parasites. Intracellular amastigote screening will be employed as the most relevant for *Leishmania* spp and *T. cruzi*. Compound libraries (focused, diversity oriented or natural) will be screened in these systems, as well as compound series devised through target screening and in silico approaches. For carefully chosen protein targets, all three kinetoplastid parasite homologues will be screened against the closest human homologue to establish selectivity.

Promising lead compounds will be optimised for efficacy and tolerability in cell-based and animal disease models. Toxicological markers will be evaluated in human cell lines prior to toxicity (acute, subacute, chronic) testing in lower then higher mammals. In parallel, and in line with the FDA's ‘Critical Path Initiative’, several check point controls will be built into the pipeline to flag, identify and allow early correction of potential toxicity/efficacy issues. These will include (i) a systems biology approach to identify drug target and off-target interactions via activity-based chemoproteomics (ii) ‘uptake and metabolism’ as potential modulators of drug efficacy and/or resistance and (iii) the establishment of a firm set of rules for drug efficacy and safety in kinetoplastid chemotherapy. Our goal is to strengthen the drug development pipeline in order to achieve at least one new Phase I clinical candidate for each trypanosomatid disease at or shortly after the project completion date.



**EUROPEAN
COMMISSION**

**FP7 Specific Programme
IDEAS**



Perfil pretendido:

Licenciatura em Ciências da Saúde ou afins com classificação final igual ou superior a 16 valores. Dá-se preferência a candidatos com experiência em técnicas de Biologia Molecular e Celular e com capacidades de organização do laboratório. Exige-se domínio da língua Inglesa, falada e escrita e bom relacionamento inter-pessoal num contexto de uma equipa de investigação multidisciplinar e grande motivação para o trabalho multidisciplinar.

O prazo para recepção de candidaturas decorre de 22 de janeiro a 4 de fevereiro de 2016.

As propostas deverão incluir uma carta de motivação (onde deve explicitar a bolsa a que se candidata), CV e 2 cartas de recomendação e ser submetidas no site do IBMC: <http://www.ibmc.up.pt/gestaocandidaturas/index.php?codigo=PR301601>

A contratação será regida pelo estipulado na legislação em vigor, nomeadamente o “Estatuto do Bolseiro de Investigação Científica, aprovado pela Lei nº 40/2004, de 18 de agosto, alterado e republicado pelo Decreto-Lei nº 202/2012, de 27 de agosto.”, e o Regulamento de Bolsas de Investigação Científica do IBMC (www.ibmc.up.pt/fellowships.php).



**EUROPEAN
COMMISSION**

**FP7 Specific Programme
IDEAS**

